摘要
目的:探讨了肺癌患者化疗前后血清IGF-Ⅱ、CA19-9和VEGF水平变化及临床意义。方法:应用放射免疫分析和酶联法对31例肺癌患者进行了血清IGF-Ⅱ、CA19-9和VEGF检测,并与35例正常人作比较。结果:化疗前血清IGF-Ⅱ、CA19-9和VEGF水平非常显著地高于正常人组(P<0.01),经化疗1个月后则与正常人组比较无显著性差异(P>0.05),血清IGF-Ⅱ、CA19-9和VEGF水平呈正相关(r=0.5928、0.6024,P<0.01)。结论:测定肺癌患者化疗前后血清IGF-Ⅱ、CA19-9和VEGF水平的变化对了解病情和预后观察均具有重要的临床价值。
Objective To explore the clinical significance of changes of serum IGF-Ⅱ, CA19-9 and VEGF levels after chemotherapy in patients with lung cancer. Methods Serum IGF-Ⅱ, CA19-9 （with RIA） and VEGF （with ELISA） levels were determined in 31 patients with lung cancer both before and after chemotherapy as well as in 35 controls. Results Before chemotherapy, serum IGF-Ⅱ, CA19-9 and VEGF levels were significantly higher in the patients with those in controls （P〈0.01）. After chemotherapy for one month, serum IGF-Ⅱ, CA19-9 and VEGF levels were approaching normal vs controls （P〉0.05）. Serum IGF-Ⅱ and CA19-9 levels were positively correlated with VEGF levels （r=0.5928, 0.6024, P〈0.01）. Conclusion Changes of serum IGF-Ⅱ, CA19-9 and VEGF levels are closely related to the tumor burden.
出处
《放射免疫学杂志》
CAS
2010年第6期622-623,共2页
Journal of Radioimmanology
关键词
肺癌
胰岛素样生长因子-Ⅱ
糖类抗原19-9
血管内皮生长因子
lung cancer
insulin-like growth factor （IGF-Ⅱ）
carbohydrate antigen 19-9 （CA19-9）
vascular endothelial growth factor （VEGF）
